Regeneron Wins FDA Approval for Pasatru to Treat Rare Bone Disorder

Regeneron $REGN secures FDA approval for Pasatru to treat an ultra-rare bone growth disease. Pasatru targets fibrodysplasia ossificans progressiva (FOP), an illness causing bone to accumulate and lock up limbs. Patients with the disease typically rely on wheelchairs by age 25. Life expectancy remains severely reduced, with only some individuals living into their 50s. The medical approval caps a three-decade effort the company saw through. "Having an effective treatment, you’re hoping that you’ll change that trajectory. You’re almost completely stopping the new [bone] forming, and therefore their condition will not deteriorate." — Richard Keen The clearance gives doctors a targeted clinical mechanism to intervene in a disease that historically offered no recourse.